FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Med (Auckl) / Use of firocoxib for the treatment of equine osteoarthritis.
Veterinary medicine (Auckland, N.Z.)2014; 5; 159-168; doi: 10.2147/VMRR.S70207

Use of firocoxib for the treatment of equine osteoarthritis.

Abstract: This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1-3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date.
© 2014 Donnell and Frisbie.
Get Full Text
Publication Date: 2014-11-04 PubMed ID: 32670856PubMed Central: PMC7337192DOI: 10.2147/VMRR.S70207Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article delves into the methods and benefits of treating equine osteoarthritis with a drug called firocoxib. It discusses the reduction of symptoms and the necessity for further research to understand its potential as a disease-modifying drug.

Understanding the Pathogenesis and Medical Treatment of Equine Osteoarthritis

  • The paper discusses the pathogenesis (the biological mechanism that leads to a disease) and medical treatment of equine osteoarthritis, which involves inflammation and degeneration of joints in horses.
  • It highlights the inhibition of a compound called prostaglandin E as a crucial part of managing symptoms like pain and lameness in horses afflicted with osteoarthritis.

The Role of NSAIDs and Firocoxib in Treatment

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually used to inhibit the production of prostaglandin E from the arachidonic acid pathway. This is necessary because prostaglandin E can cause inflammation and pain.
  • The paper explores the use of firocoxib, a ‘COX-2-preferential’ NSAID, which means it mainly inhibits the COX-2 enzyme responsible for producing prostaglandins.
  • Firocoxib has been found to be safe for use in horses, and approximately 70% of the drug is available in the body for therapeutic effect after oral administration, a characteristic known as oral bioavailability.

The Impact and Dosage of Firocoxib

  • Three clinical reports mentioned in the paper show that firocoxib can effectively reduce symptoms such as pain and lameness when given once daily for seven days.
  • A one-time loading dose can bring about improvement within a faster timeframe—1 to 3 days—as compared to smaller doses.

The Need for Further Investigation

  • The paper highlights that while other COX-2-preferential NSAIDs like meloxicam and carprofen have shown significant disease-modifying effects, similar in-depth studies have not been conducted for firocoxib. This signals a need for further research to understand firocoxib’s full potential in treating equine osteoarthritis.

Cite This Article

APA
Donnell JR, Frisbie DD. (2014). Use of firocoxib for the treatment of equine osteoarthritis. Vet Med (Auckl), 5, 159-168. https://doi.org/10.2147/VMRR.S70207

Publication

Veterinary medicine (Auckland, N.Z.)
ISSN: 2230-2034
NlmUniqueID: 101724251
Country: New Zealand
Language: English
Volume: 5
Pages: 159-168

Researcher Affiliations

Donnell, Josh R
  • Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA.
Frisbie, David D
  • Department of Clinical Sciences, Orthopedic Research Center, Colorado State University, Fort Collins, CO, USA.

Conflict of Interest Statement

None of the authors has a financial interest or a personal relationship with other people or organizations that could inappropriately influence or bias the content of this review article.

References

This article includes 76 references
  1. Ross MW, Dyson SJ. Diagnosis and Management of Lameness in the Horse. Philadelphia, PA, WB Saunders, 2003, 1140p.
  2. United States Department of Agriculture. National Economic Cost of Equine Lameness, Colic and Equine Protozoal Myeloencephalitis in the United States. Washington: USDA; 2001.
  3. McIlwraith CW, Vachon A. Review of pathogenesis and treatment of degenerative joint disease.. Equine Vet J Suppl 1988 Sep;(6):3-11.
    pubmed: 9079056doi: 10.1111/j.2042-3306.1988.tb04641.xgoogle scholar: lookup
  4. . Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section.. Ann Rheum Dis 1996 Aug;55(8):552-7.
    pmc: PMC1010237pubmed: 8774185doi: 10.1136/ard.55.8.552google scholar: lookup
  5. Lynch TM, Caron JP, Arnoczky SP, Lloyd JW, Stick JA, Render JA. Influence of exogenous hyaluronan on synthesis of hyaluronan and collagenase by equine synoviocytes.. Am J Vet Res 1998 Jul;59(7):888-92.
    pubmed: 9659557
  6. Kawcak CE, Frisbie DD, McIlwraith CW, Werpy NM, Park RD. Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis.. Am J Vet Res 2007 Jun;68(6):598-604.
    pubmed: 17542691doi: 10.2460/ajvr.68.6.598google scholar: lookup
  7. Gotoh S, Onaya J, Abe M, Miyazaki K, Hamai A, Horie K, Tokuyasu K. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats.. Ann Rheum Dis 1993 Nov;52(11):817-22.
    pmc: PMC1005195pubmed: 8250613doi: 10.1136/ard.52.11.817google scholar: lookup
  8. Frisbie DD, McIlwraith CW, Kawcak CE, Werpy NM, Pearce GL. Evaluation of topically administered diclofenac liposomal cream for treatment of horses with experimentally induced osteoarthritis.. Am J Vet Res 2009 Feb;70(2):210-5.
    pubmed: 19231953doi: 10.2460/ajvr.70.2.210google scholar: lookup
  9. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.. Am J Vet Res 2007 Mar;68(3):290-6.
    pubmed: 17331019doi: 10.2460/ajvr.68.3.290google scholar: lookup
  10. Frisbie DD, Kawcak CE, Trotter GW, Powers BE, Walton RM, McIlwraith CW. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model.. Equine Vet J 1997 Sep;29(5):349-59.
    pubmed: 9306060doi: 10.1111/j.2042-3306.1997.tb03138.xgoogle scholar: lookup
  11. Clegg TE, Caborn D, Mauffrey C. Viscosupplementation with hyaluronic acid in the treatment for cartilage lesions: a review of current evidence and future directions.. Eur J Orthop Surg Traumatol 2013 Feb;23(2):119-24.
    pubmed: 23412441doi: 10.1007/s00590-012-0940-0google scholar: lookup
  12. Dechant JE, Baxter GM, Frisbie DD, Trotter GW, McIlwraith CW. Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro.. Equine Vet J 2003 Jul;35(5):444-50.
    pubmed: 12875321doi: 10.2746/042516403775600479google scholar: lookup
  13. Kawcak CE, Norrdin RW, Frisbie DD, Trotter GW, Mcilwraith CW. Effects of osteochondral fragmentation and intra-articular triamcinolone acetonide treatment on subchondral bone in the equine carpus.. Equine Vet J 1998 Jan;30(1):66-71.
    pubmed: 9458401doi: 10.1111/j.2042-3306.1998.tb04090.xgoogle scholar: lookup
  14. Mitsui Y, Gotoh M, Nakama K, Yamada T, Higuchi F, Nagata K. Hyaluronic acid inhibits mRNA expression of proinflammatory cytokines and cyclooxygenase-2/prostaglandin E(2) production via CD44 in interleukin-1-stimulated subacromial synovial fibroblasts from patients with rotator cuff disease.. J Orthop Res 2008 Jul;26(7):1032-7.
    pubmed: 18302264doi: 10.1002/jor.20558google scholar: lookup
  15. Doucet MY, Bertone AL, Hendrickson D, Hughes F, Macallister C, McClure S, Reinemeyer C, Rossier Y, Sifferman R, Vrins AA, White G, Kunkle B, Alva R, Romano D, Hanson PD. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.. J Am Vet Med Assoc 2008 Jan 1;232(1):91-7.
    pubmed: 18167116doi: 10.2460/javma.232.1.91google scholar: lookup
  16. Frisbie DD. Equine surgery. In: Auer JA, Stick JA, editors. Musculoskeletal System: Medical Treatment of Joint Disease. 4th ed. St Louis (MO): Elsevier Saunders; 2012: 1114–1122.
  17. Kvaternick V, Malinski T, Wortmann J, Fischer J. Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma.. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Jul 1;854(1-2):313-9.
    pubmed: 17537684doi: 10.1016/j.jchromb.2007.04.037google scholar: lookup
  18. Cox S, Dudenbostel L, Sommardahl C, Yarbrough J, Saleh M, Doherty T. Pharmacokinetics of firocoxib and its interaction with enrofloxacin in horses.. J Vet Pharmacol Ther 2012 Dec;35(6):615-7.
    pubmed: 22233122doi: 10.1111/j.1365-2885.2011.01362.xgoogle scholar: lookup
  19. McIlwraith CW. From arthroscopy to gene therapy–30 years of looking in joints. Am Assoc Equine Pract 2005;51:65–113.
  20. McIlwraith CW. Current concepts in equine degenerative joint disease.. J Am Vet Med Assoc 1982 Feb 1;180(3):239-50.
    pubmed: 7035425
  21. McIlwraith CW, Van Sickle DC. Experimentally induced arthritis of the equine carpus: histologic and histochemical changes in the articular cartilage.. Am J Vet Res 1981 Feb;42(2):209-17.
    pubmed: 7258770
  22. McIlwraith CW, Vachon A. Review of pathogenesis and treatment of degenerative joint disease.. Equine Vet J Suppl 1988 Sep;(6):3-11.
    pubmed: 9079056doi: 10.1111/j.2042-3306.1988.tb04641.xgoogle scholar: lookup
  23. Greenwald RA, Moy WW. Inhibition of collagen gelation by action of the superoxide radical.. Arthritis Rheum 1979 Mar;22(3):251-9.
    pubmed: 217393doi: 10.1002/art.1780220307google scholar: lookup
  24. Dimock AN, Siciliano PD, McIlwraith CW. Evidence supporting an increased presence of reactive oxygen species in the diseased equine joint.. Equine Vet J 2000 Sep;32(5):439-43.
    pubmed: 11037267doi: 10.2746/042516400777591129google scholar: lookup
  25. May SA, Lees P. Nonsteroidal anti-inflammatory drugs. In: McIlwraith CW, Trotter GW, editors. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996: 223–237.
  26. Frisbie DD, Al-Sobayil F, Billinghurst RC, Kawcak CE, McIlwraith CW. Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses.. Osteoarthritis Cartilage 2008 Oct;16(10):1196-204.
    pubmed: 18442931doi: 10.1016/j.joca.2008.03.008google scholar: lookup
  27. Frisbie DD, Kawcak CE, Baxter GM, Trotter GW, Powers BE, Lassen ED, McIlwraith CW. Effects of 6alpha-methylprednisolone acetate on an equine osteochondral fragment exercise model.. Am J Vet Res 1998 Dec;59(12):1619-28.
    pubmed: 9858417
  28. Kawcak CE, Frisbie DD, Trotter GW, McIlwraith CW, Gillette SM, Powers BE, Walton RM. Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation.. Am J Vet Res 1997 Oct;58(10):1132-40.
    pubmed: 9328667
  29. Teitz CC, Chrisman OD. The effect of salicylate and chloroquine on prostaglandin-induced articular damage in the rabbit knee.. Clin Orthop Relat Res 1975 May;(108):264-74.
    pubmed: 49235doi: 10.1097/00003086-197505000-00039google scholar: lookup
  30. Tung JT, Arnold CE, Alexander LH, Yuzbasiyan-Gurkan V, Venta PJ, Richardson DW, Caron JP. Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1beta-stimulated matrix metalloproteinases 1, 3, and 13 and tissue inhibitor of matrix metalloproteinase 1 expression in equine chondrocyte cultures.. Am J Vet Res 2002 Jul;63(7):987-93.
    pubmed: 12118680doi: 10.2460/ajvr.2002.63.987google scholar: lookup
  31. Goldring MB, Suen LF, Yamin R, Lai WF. Regulation of Collagen Gene Expression by Prostaglandins and Interleukin-1beta in Cultured Chondrocytes and Fibroblasts.. Am J Ther 1996 Jan;3(1):9-16.
    pubmed: 11856992doi: 10.1097/00045391-199601000-00003google scholar: lookup
  32. DiBattista JA, Martel-Pelletier J, Fujimoto N, Obata K, Zafarullah M, Pelletier JP. Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway.. Lab Invest 1994 Aug;71(2):270-8.
    pubmed: 8078306
  33. Pettersson H, Rydén G. Avulsion fractures of the caudoproximal extremity of the first phalanx.. Equine Vet J 1982 Oct;14(4):333-5.
    pubmed: 7173145doi: 10.1111/j.2042-3306.1982.tb02447.xgoogle scholar: lookup
  34. Nilsson G, Olsson SE. Radiologic and patho-anatomic changes in the distal joints and the phalanges of the standardbred horse.. Acta Vet Scand Suppl 1973;44(0):1-57.
    pubmed: 4529375
  35. Nilsson G. Lameness and pathologic changes in the distal joints and the phalanges of the standardbred horse. A correlative study.. Acta Vet Scand Suppl 1973;44(0):83-96.
    pubmed: 4529326
  36. Barclay WP, Foerner JJ, Phillips TN. Lameness attributable to osteochondral fragmentation of the plantar aspect of the proximal phalanx in horses: 19 cases (1981-1985).. J Am Vet Med Assoc 1987 Oct 1;191(7):855-7.
    pubmed: 3679979
  37. McIlwraith CW, Trotter GW. Clinical feature and diagnosis of equine joint disease. In: McIlwraith CW, Trotter GW, editors. Joint Disease in the Horse. Philadelphia: WB Saunders; 1996;120–145.
  38. van Weeren PR, de Grauw JC. Pain in osteoarthritis.. Vet Clin North Am Equine Pract 2010 Dec;26(3):619-42.
    pubmed: 21056303doi: 10.1016/j.cveq.2010.07.007google scholar: lookup
  39. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.. Nat New Biol 1971 Jun 23;231(25):232-5.
    pubmed: 5284360doi: 10.1038/newbio231232a0google scholar: lookup
  40. Dingle JT. Prostaglandins in human cartilage metabolism.. J Lipid Mediat 1993 Mar-Apr;6(1-3):303-12.
    pubmed: 8357988
  41. Barton MH, Paske E, Norton N, King D, Giguère S, Budsberg S. Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses.. Equine Vet J 2014 Jan;46(1):72-5.
    pmc: PMC3805772pubmed: 23662599doi: 10.1111/evj.12095google scholar: lookup
  42. Duz M, Parkin TD, Cullander RM, Marshall JF. Effect of flunixin meglumine and firocoxib on ex vivo cyclooxygenase activity in horses undergoing elective surgery.. Am J Vet Res 2015 Mar;76(3):208-15.
    pubmed: 25710756doi: 10.2460/ajvr.76.3.208google scholar: lookup
  43. McCann M, Anderson D, Brideau C, Black WC, Zhang GH, Hickey GJ. In vitro activity and in vivo efficacy of a novel COX-2 inhibitor in the horse. J Vet Intern Med 2002;16:355.
  44. Cox S, Villarino N, Sommardahl C, Kvaternick V, Zarabadipour C, Siger L, Yarbrough J, Amicucci A, Reed K, Breeding D, Doherty T. Disposition of firocoxib in equine plasma after an oral loading dose and a multiple dose regimen.. Vet J 2013 Nov;198(2):382-5.
    pubmed: 24076125doi: 10.1016/j.tvjl.2013.07.035google scholar: lookup
  45. Hovanessian N, Davis JL, McKenzie HC 3rd, Hodgson JL, Hodgson DR, Crisman MV. Pharmacokinetics and safety of firocoxib after oral administration of repeated consecutive doses to neonatal foals.. J Vet Pharmacol Ther 2014 Jun;37(3):243-51.
    pubmed: 24749691doi: 10.1111/jvp.12082google scholar: lookup
  46. Knych HK, Stanley SD, Arthur RM, Mitchell MM. Detection and pharmacokinetics of three formulations of firocoxib following multiple administrations to horses.. Equine Vet J 2014 Nov;46(6):734-8.
    pubmed: 24393414doi: 10.1111/evj.12211google scholar: lookup
  47. Racing Medication and Testing Consortium. Controlled therapeutic medications. 2013.
  48. Kvaternick V, Pollmeier M, Fischer J, Hanson PD. Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses.. J Vet Pharmacol Ther 2007 Jun;30(3):208-17.
    pubmed: 17472652doi: 10.1111/j.1365-2885.2007.00840.xgoogle scholar: lookup
  49. United States Equestrian Federation. 2014 Guidelines for Drugs and Medications. Columbus (OH): USEF; 2014.
  50. Letendre LT, Tessman RK, McClure SR, Kvaternick VJ, Fischer JB, Hanson PD. Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses.. Am J Vet Res 2008 Nov;69(11):1399-405.
    pubmed: 18980421doi: 10.2460/ajvr.69.11.1399google scholar: lookup
  51. Lees P. Analgesic, antiinflammatory, antipyretic drugs. In: Riviere JE, Papich MG. Veterinary Pharmacology and Therapeutics. 9th ed. Ames (IA): Wiley-Blackwell; 2009: 457–492.
  52. US Food and Drug Administration. Freedom of Information Summary: Equioxx Oral Paste–0.82% Firocoxib (w/w). Rockville (MD): FDA; 2005.
  53. Orsini JA, Ryan WG, Carithers DS, Boston RC. Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses.. Am J Vet Res 2012 May;73(5):664-71.
    pubmed: 22533398doi: 10.2460/ajvr.73.5.664google scholar: lookup
  54. Koene M, Goupil X, Kampmann C, Hanson PD, Denton D, Pollmeier MG. Field trial validation of the efficacy and acceptability of firocoxib, a highly selective COX-2 inhibitor, in a group of 96 lame horses. J Equine Vet Sci 2010;30:237–243.
  55. Kivett L, Taintor J, Wright J. Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses.. J Vet Pharmacol Ther 2014 Aug;37(4):413-6.
    pubmed: 24354928doi: 10.1111/jvp.12097google scholar: lookup
  56. US Food and Drug Administration. Freedom of Information Summary: Equioxx Injection–firocoxib. Rockville (MD): FDA; 2010.
  57. Wallace JL, Reuter BK, McKnight W, Bak A. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe?. J Clin Gastroenterol 1998;27 Suppl 1:S28-34.
    pubmed: 9872495doi: 10.1097/00004836-199800001-00006google scholar: lookup
  58. Nieto JE, Aleman M, Anderson JD, Fiack C, Snyder JR. Effects of phenylbutazone on gene expression of cyclooxygenase-1 and -2 in the oral, glandular gastric, and bladder mucosae of healthy horses.. Am J Vet Res 2012 Jan;73(1):98-104.
    pubmed: 22204294doi: 10.2460/ajvr.73.1.98google scholar: lookup
  59. Cook VL, Meyer CT, Campbell NB, Blikslager AT. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum.. Am J Vet Res 2009 Aug;70(8):992-1000.
    pubmed: 19645580doi: 10.2460/ajvr.70.8.992google scholar: lookup
  60. MacKay RJ, French TW, Nguyen HT, Mayhew IG. Effects of large doses of phenylbutazone administration to horses.. Am J Vet Res 1983 May;44(5):774-80.
    pubmed: 6869982
  61. MacAllister CG. Effects of toxic doses of phenylbutazone in ponies.. Am J Vet Res 1983 Dec;44(12):2277-9.
    pubmed: 6660616
  62. Back W, MacAllister CG, van Heel MC, Pollmeier M, Hanson PD. The use of force plate measurements to titrate the dosage of a new COX-2 inhibitor in lame horses.. Equine Vet J 2009 Mar;41(3):309-12.
    pubmed: 19469242doi: 10.2746/042516409x397118google scholar: lookup
  63. Collins LG, Tyler DE. Phenylbutazone toxicosis in the horse: a clinical study.. J Am Vet Med Assoc 1984 Mar 15;184(6):699-703.
    pubmed: 6725103
  64. Keegan KG, Messer NT, Reed SK, Wilson DA, Kramer J. Effectiveness of administration of phenylbutazone alone or concurrent administration of phenylbutazone and flunixin meglumine to alleviate lameness in horses.. Am J Vet Res 2008 Feb;69(2):167-73.
    pubmed: 18241011doi: 10.2460/ajvr.69.2.167google scholar: lookup
  65. Owens JG, Kamerling SG, Barker SA. Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis.. J Vet Pharmacol Ther 1995 Jun;18(3):187-95.
    pubmed: 7674454doi: 10.1111/j.1365-2885.1995.tb00577.xgoogle scholar: lookup
  66. Owens JG, Kamerling SG, Stanton SR, Keowen ML, Prescott-Mathews JS. Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses.. Am J Vet Res 1996 Jun;57(6):866-74.
    pubmed: 8725815
  67. Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.. Pharmacol Res 2005 Oct;52(4):302-6.
    pubmed: 15939622doi: 10.1016/j.phrs.2005.04.004google scholar: lookup
  68. Lees P, McKellar Q, May SA, Ludwig B. Pharmacodynamics and pharmacokinetics of carprofen in the horse.. Equine Vet J 1994 May;26(3):203-8.
    pubmed: 8542839doi: 10.1111/j.2042-3306.1994.tb04370.xgoogle scholar: lookup
  69. Raidal SL, Edwards S, Pippia J, Boston R, Noble GK. Pharmacokinetics and safety of oral administration of meloxicam to foals.. J Vet Intern Med 2013 Mar-Apr;27(2):300-7.
    pubmed: 23425143doi: 10.1111/jvim.12045google scholar: lookup
  70. Vander Werf KA, Davis EG, Kukanich B. Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses.. J Vet Pharmacol Ther 2013 Aug;36(4):376-81.
    pubmed: 23067209doi: 10.1111/jvp.12021google scholar: lookup
  71. Sanderson RO, Beata C, Flipo RM, Genevois JP, Macias C, Tacke S, Vezzoni A, Innes JF. Systematic review of the management of canine osteoarthritis.. Vet Rec 2009 Apr 4;164(14):418-24.
    pubmed: 19346540doi: 10.1136/vr.164.14.418google scholar: lookup
  72. Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs.. J Vet Intern Med 2013 Sep-Oct;27(5):1011-9.
    pubmed: 23782347doi: 10.1111/jvim.12127google scholar: lookup
  73. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis.. Equine Vet J 2009 Sep;41(7):693-9.
    pubmed: 19927589doi: 10.2746/042516409x436286google scholar: lookup
  74. McKellar QA, Bogan JA, von Fellenberg RL, Ludwig B, Cawley GD. Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse.. Equine Vet J 1991 Jul;23(4):280-4.
    pubmed: 1915228doi: 10.1111/j.2042-3306.1991.tb03718.xgoogle scholar: lookup
  75. Liesegang A, Limacher S, Sobek A. The effect of carprofen on selected markers of bone metabolism in dogs with chronic osteoarthritis.. Schweiz Arch Tierheilkd 2007 Aug;149(8):353-62.
    pubmed: 17803115doi: 10.1024/0036-7281.149.8.353google scholar: lookup
  76. Williams A, Smith JR, Allaway D, Harris P, Liddell S, Mobasheri A. Carprofen inhibits the release of matrix metalloproteinases 1, 3, and 13 in the secretome of an explant model of articular cartilage stimulated with interleukin 1β.. Arthritis Res Ther 2013;15(6):R223.
    pmc: PMC3978949pubmed: 24373218doi: 10.1186/ar4424google scholar: lookup

Citations

This article has been cited 1 times.
  1. Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses.. Vet Anim Sci 2023 Mar;19:100286.
    doi: 10.1016/j.vas.2023.100286pubmed: 36684818google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.